Cargando…
Clinical Pharmacokinetics of Clopidogrel and Its Metabolites in Patients with Cardiovascular Diseases
BACKGROUND AND OBJECTIVE: Approximately 5–40 % of patients treated with clopidogrel do not display an adequate antiplatelet response. Clopidogrel resistance may be caused by insufficient drug absorption or impaired metabolic activation of the drug. The aim of this study was to evaluate the pharmacok...
Autores principales: | Karaźniewicz-Łada, Marta, Danielak, Dorota, Burchardt, Paweł, Kruszyna, Łukasz, Komosa, Anna, Lesiak, Maciej, Główka, Franciszek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899497/ https://www.ncbi.nlm.nih.gov/pubmed/24127209 http://dx.doi.org/10.1007/s40262-013-0105-2 |
Ejemplares similares
-
Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite
por: Danielak, Dorota, et al.
Publicado: (2017) -
Impact of CYP3A4*1G Allele on Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel
por: Danielak, Dorota, et al.
Publicado: (2016) -
Vitamin D Receptor Gene Polymorphism and Vitamin D Status in Population of Patients with Cardiovascular Disease—A Preliminary Study
por: Abouzid, Mohamed, et al.
Publicado: (2021) -
Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins
por: Danielak, Dorota, et al.
Publicado: (2018) -
Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
por: Karaźniewicz-Łada, Marta, et al.
Publicado: (2021)